Vertex announces uk mhra approval of alyftrek® (deutivacaftor/tezacaftor/vanzacaftor), a once-daily next-in-class cftr modulator for the treatment of cystic fibrosis

London--(business wire)--vertex pharmaceuticals (nasdaq: vrtx) announced today that the united kingdom (uk) medicines and healthcare products regulatory agency (mhra) has granted approval for alyftrek® (deutivacaftor/tezacaftor/vanzacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (cftr) modulator treatment for people living with cystic fibrosis (cf) ages 6 years and older who have at least one f508del mutation or another responsive muta.
VRTX Ratings Summary
VRTX Quant Ranking